Last updated: 2023-11-19

Unique indications: 1014

Unique indications - of which genetic insight: 769

Unique targets: 2241

Unique T-I: 18787

Unique D-T-I: 46015

Approved | Unique targets: 311

Approved | Unique indications: 432

Approved | Unique T-I: 942

Historical | Unique targets: 1923

Historical | Unique indications: 793

Historical | Unique T-I: 11730

Active | Unique targets: 1310

Active | Unique indications: 686

Active | Unique T-I: 6115

Merged sim ≥0.8 | Unique targets: 686

Merged sim ≥0.8 | Unique indications: 364

Merged sim ≥0.8 | Unique T-I (all): 1521

Merged sim ≥0.8 | Unique T-I (meeting default criteria): 558

Merged sim ≥0.8 | Unique T-I-A: 2088

Assocs | Unique T-A: 81939

Assocs | OTG | Unique T-A (all): 172046

Assocs | OTG | Unique T-A (L2G >= 0.5): 66203

Assocs | OMIM | Unique T-A: 4510

Assocs | PICCOLO | Unique T-A: 8186

Assocs | Genebass | Unique T-A: 4313

Assocs | intOGen | Unique T-A: 2506

Pharmaprojects | MeSH missing from sim matrix: 7/977

Pharmaprojects | MeSH present in sim matrix: 970/977

Pharmaprojects | proportion of unique MeSH in sim matrix: 99.284%

Pharmaprojects | proportion assoc rows in sim matrix: 99.946%

Assocs | MeSH missing from sim matrix: 2/2262

Assocs | MeSH present in sim matrix: 2260/2262

Assocs | proportion of unique MeSH in sim matrix: 99.912%

Assocs | proportion assoc rows in sim matrix: 99.999%

Logit model launched ~ assoc_year: beta = -0.026, P = 0.43

Logit model launched ~ gene_count: beta = 0.00056, P = 0.036

Enrichment of top 3 highest-RS therapy areas for gene_count >= 100: OR = 3.1, P = 0.000053

Logit model launched ~ abs_beta: beta = 0.011, P = 0.83

Logit model launched ~ abs_or: beta = -0.017, P = 0.81

Logit model launched ~ lead_maf: beta = 0.74, P = 0.46

Combined P(G) for Launched T-I: 14.6%

Combined P(G) for all active clinical T-I: 6.5% (218/3359)

Combined P(G) for all historical clinical T-I: 5.2% (401/7744)

Indications with 0 supported genes: 179

Genetic support for launched T-I from OTG was retrospective (min_assoc_year >= year_launch) in 10/24 (42%) instances

CMH test on I-Launched RS values across 17 therapy areas: P = 1.0e-15

For all time, of 517 launched targets, the 74 with ≥10 launched indications account for 1243 of 2492 launched indications (50%)

Since 2000 only, of 311 launched targets, the 14 with ≥10 launched indications account for 241 of 940 launched indications (26%)

Spearman's correlation n_launched_indic vs. meansim across targets: rho = -0.721, P = 4.4e-84

Logit model gensup ~ ipert: beta = -0.0532, P = 2.3e-05

Logit model gensup ~ ipert without 1-indication targets: beta = -0.0373, P = 3.1e-03

Logit model gensup ~ meansim: beta = 1.39, P = 2.1e-04

Logit model gensup ~ meansim without 1-indication targets: beta = -0.718, P = 3.4e-01

Weighted Pearson correlation across areas, poss_supp_gi vs. rs: rho= 0.54, P = 2.50e-02

Spearman correlation n_launched_indic vs. mean_sim: rho= -0.72, P = 0.0000000000000000000000000000000000000000000000000000000000000000000000000000000000044

Weighted Pearson correlation across areas, mean_sim vs. rs: rho= 0.59, P = 0.012

Weighted Pearson correlation across areas, indic per target vs. rs: rho= -0.47, P = 0.06

Confounding between therapy area and year of discovery among OTG GWAS Catalog-supported T-I pairs: KW test P = 1.2e-05, Chi Square test P = 3.6e-09

Confounding between therapy area and gene count among OTG GWAS Catalog-supported T-I pairs: KW test P = 2.1e-20, Chi Square test P = 6.6e-30

Confounding between therapy area and beta among OTG GWAS Catalog-supported T-I pairs: KW test P = 1.7e-06, Chi Square test P = 4.3e-03

Confounding between therapy area and OR among OTG GWAS Catalog-supported T-I pairs: KW test P = 5.6e-05, Chi Square test P = 6.6e-06

Confounding between therapy area and MAF among OTG GWAS Catalog-supported T-I pairs: KW test P = 1.4e-01, Chi Square test P = 5.6e-02

Confounding between therapy area and GWAS source: Chi Square test P = 1.2e-03

Weighted Pearson's correlation P(G) vs P(S) across areas: rho = 0.722, P = 1.1e-03

Weighted Pearson's correlation P(S) vs RS across areas: rho = 0.164, P = 5.3e-01

Weighted Pearson's correlation P(G) vs RS across areas: rho = 0.568, P = 1.7e-02

Overall RS from Nelson 2015: 2.02 vs. current study: 2.51

T-I in Phase I-III with genetic support: 401/7744 historical vs. 218/3359 active. OR = 1.3, P = 0.0069

Fisher's test for enrichment of genetically supported T-I pairs among those developed: OR= 12.0, P = 0.00e+00

Space of possible T-I pairs: 19338 genes times 769 indications with genetic insight = 14,870,922 T-I pairs

Number of possible T-I pairs with genetic support: 101954 = 0.69%

Number of clinically developed T-I pairs: 9649

Number of clinically developed T-I pairs with genetic support: 721 = 0.71% of possible / 7.47% of Phase I+

After removing heavy hitters and restricting to most similar indications, the number of possible T-I pairs with genetic support: 34190 = 0.23%

Number of clinically developed T-I pairs with genetic support: 478 = 1.40%

Of targets with both ≥1 supported indication and ≥1 Phase I+ indication, 70% (652/937) have been developed only for unsupported indications.

Of targets with both ≥1 supported indication and ≥1 Phase I+ indication, 7% (63/937) have been developed only for supported indications.

Of targets with both ≥1 supported indication and ≥1 Phase I+ indication, 24% (222/937) have been developed for both.

Of targets with both ≥1 supported indication and ≥1 Phase I+ indication, there were 6880 unsupported indications and 478 supported indications pursued, a ratio of 14.4

Of launched targets with both ≥1 supported indication and ≥1 Phase I+ indication, there were 3435 unsupported indications and 260 supported indications pursued, a ratio of 13.2

Of non-launched targets with both ≥1 supported indication and ≥1 Phase I+ indication, there were 3445 unsupported indications and 218 supported indications pursued, a ratio of 15.8

Fisher test for difference between these ratios: OR=1.2, P=0.06.

Ordinal logistic model for drug-indication advancement: genetic support beta= 0.57, P = 2.24e-56

